http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112694474-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-416 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2019-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112694474-B |
| titleOfInvention | Indazole derivative and preparation method and application thereof |
| abstract | The invention relates to indazole derivatives, a preparation method and application thereof, belonging to the field of chemical medicine. The invention provides a compound shown as a formula I or a pharmaceutically acceptable salt thereof. The invention also provides a preparation method and application of the compound. Biological experiments show that the compounds have obvious inhibition effect on FGFR1, and partial compounds can effectively inhibit cancer cells such as breast cancer cells, colorectal cancer cells, lung cancer cells and the like under the condition of single use, so that the compound has broad-spectrum anticancer effect; in addition, the pharmaceutical composition also shows obvious inhibition effect on the proliferation of fibroblasts and human hepatic stellate cells, and the effect of resisting bleomycin-induced pulmonary fibrosis in animals is equivalent to that of the currently clinically used medicament nintedanib for treating pulmonary fibrosis, and the anti-fibrosis curative effect is obvious. The invention provides a new choice for the development and application of anti-cancer and anti-fibrosis drugs. |
| priorityDate | 2019-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 166.